Fluorescence in situ hybridization as adjunct to cytology improves the diagnosis and directs estimation of prognosis of malignant pleural effusions

Journal of Cardiothoracic Surgery

Volumn 7, Issue 1, 2012, Pages

  Han, Jingquan ^a   Cao, Shouqiang ^a   Zhang, Kai ^a   Zhao, Guibin ^a   Xin, Yanzhong ^a   Dong, Qing ^a   Yan, Yubo ^a   Cui, Jian ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

FISH; Malignant pleural effusions; Prognosis; Sensitivity; Specificity

Indexed keywords

ADULT; AGED; ARTICLE; CHEMISTRY; COHORT ANALYSIS; CYTOCHEMISTRY; CYTOLOGY; EXUDATE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; HUMAN CHROMOSOME; MALE; METHODOLOGY; MIDDLE AGED; NEOPLASM; PATHOLOGY; PLEURA EFFUSION; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN; COHORT STUDIES; EXUDATES AND TRANSUDATES; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84868667919     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-7-121     Document Type: Article

References (27)

1. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med 2005, 129:1421-1427.
2. Chhieng DC, Ko EC, Yee HT, Shultz JJ, Dorvault CC, Eltoum IA. Malignant pleural effusions due to small-cell lung carcinoma: a cytologic and immunocytochemical study. Diagn Cytopathol 2001, 25:356-360. 10.1002/dc.10011, 11747231.
3. DeCamp MM, Jaklitsch MT, Mentzer SJ, Harpole DH, Sugarbaker DJ. The safety and versatility of video-thoracoscopy: a prospective analysis of 895 consecutive cases. J Am Coll Surg 1995, 181:113-120.
4. Dawson AJ, Bal S, McTavish B, Tomiuk M, Schroedter I, Ahsanuddin AN, Seftel MD, Vallente R, Mai S, Cotter PD, et al. Inversion and deletion of 16q22 defined by array CGH, FISH, and RT-PCR in a patient with AML. Cancer Genet 2011, 204:344-347. 10.1016/j.cancergen.2011.05.005, 21763633.
5. Hartmann L, Biggerstaff JS, Chapman DB, Scott JM, Johnson KR, Ghirardelli KM, Fritschle WK, Martinez DL, Bennington RK, de Baca ME, et al. Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques. Am J Clin Pathol 2011, 136:712-720. 10.1309/AJCPF7NFLW8UAJEP, 22031309.
6. Panzeri E, Conconi D, Antolini L, Redaelli S, Valsecchi MG, Bovo G, Pallotti F, Vigano P, Strada G, Dalpra L, Bentivegna A. Chromosomal aberrations in bladder cancer: fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis. PLoS One 2011, 6:e24237. 10.1371/journal.pone.0024237, 3164716, 21909424.
7. Drieschner N, Rippe V, Laabs A, Dittberner L, Nimzyk R, Junker K, Rommel B, Kiefer Y, Belge G, Bullerdiek J, Sendt W. Interphase fluorescence in situ hybridization analysis detects a much higher rate of thyroid tumors with clonal cytogenetic deviations of the main cytogenetic subgroups than conventional cytogenetics. Cancer Genet 2011, 204:366-374. 10.1016/j.cancergen.2011.03.008, 21872823.
8. Herrera JC, Isaza LF, Ramirez JL, Vasquez G, Muneton CM. Detection of chromosome 17 aneuplody and TP53 gene deletion in a broad variety of solid tumors by dual-color fluorescence in situ hybridization (FISH). Biomedica 2010, 30:390-400.
9. Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas OA, Jager U, Fiegl M, Geissler K, Ludwig H, Huber H. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995, 86:3915-3921.
10. Eastmond DA, Schuler M, Rupa DS. Advantages and limitations of using fluorescence in situ hybridization for the detection of aneuploidy in interphase human cells. Mutat Res 1995, 348:153-162. 10.1016/0165-7992(95)90003-9, 8544867.
11. Fiegl M, Massoner A, Haun M, Sturm W, Kaufmann H, Hack R, Krugmann J, Fritzer-Szekeres M, Grunewald K, Gastl G. Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH). Br J Cancer 2004, 91:558-563. 10.1038/sj.bjc.6601942, 2409837, 15226776.
12. Fiegl M, Zojer N, Kaufmann H, Mullauer L, Schuster R, Huber H, Drach J. Hyperdiploidy and apparent aneusomy in mesothelial cells from non-malignant effusions as detected by fluorescence in situ hybridization (FISH). Cytometry 1999, 38:15-23. 10.1002/(SICI)1097-0320(19990215)38:1<15::AID-CYTO3>3.0.CO;2-C, 10088972.
13. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992, 117:215-220.
14. Cora T, Acar H, Ceran S, Bodur S. Analysis of chromosomes 9 and 11 aneuploidy frequency in pleural effusion of patients with and without malignancy: interphase FISH technique. Cancer Biol Ther 2005, 4:248-251. 10.4161/cbt.4.2.1573, 15753650.
15. Fiegl M, Haun M, Massoner A, Krugmann J, Muller-Holzner E, Hack R, Hilbe W, Marth C, Duba HC, Gastl G, Grunewald K. Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/mammaglobin B expression improves diagnosis of malignant effusions. J Clin Oncol 2004, 22:474-483.
16. Fiegl M, Kaufmann H, Zojer N, Schuster R, Wiener H, Mullauer L, Roka S, Huber H, Drach J. Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma. Hum Pathol 2000, 31:448-455. 10.1053/hp.2000.6550, 10821492.
17. Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002, 8:2073-2084.
18. Massoner A, Augustin F, Duba HC, Zojer N, Fiegl M. FISH cytogenetics and prognosis in breast and non-small cell lung cancers. Cytometry B Clin Cytom 2004, 62:52-56.
19. Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol 2009, 22:1044-1048. 10.1038/modpathol.2009.61, 19396150.
20. Watters AD, Going JJ, Cooke TG, Bartlett JM. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003, 77:109-114. 10.1023/A:1021399923825, 12602909.
21. Tiainen M, Tammilehto L, Rautonen J, Tuomi T, Mattson K, Knuutila S. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer 1989, 60:618-626. 10.1038/bjc.1989.326, 2247120, 2803935.
22. McManus DT, Patterson AH, Maxwell P, Hamilton PW, Anderson NH, Caughley LM, Toner PG. Interphase cytogenetics of chromosomes 11 and 17 in fine needle aspirates of breast cancer. Hum Pathol 1999, 30:137-144. 10.1016/S0046-8177(99)90267-8, 10029440.
23. Ichikawa D, Hashimoto N, Hoshima M, Yamaguchi T, Sawai K, Nakamura Y, Takahashi T, Abe T, Inazawa J. Analysis of numerical aberrations of specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer. Cancer 1996, 77:2064-2069. 10.1002/(SICI)1097-0142(19960515)77:10<2064::AID-CNCR15>3.0.CO;2-T, 8640671.
24. Vicidomini G, Santini M, Fiorello A, Parascandolo V, Calabro B, Pastore V. Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer?. Ann Thorac Surg 2005, 79:254-257. discussion 254-257, 10.1016/j.athoracsur.2004.06.115, 15620952.
25. Doelken P. Management of pleural effusion in the cancer patient. Semin Respir Crit Care Med 2010, 31:734-742. 10.1055/s-0030-1269833, 21213205.
26. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, Wood CG, Gu J, Wu X. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 2009, 125:2342-2348. 10.1002/ijc.24642, 2768265, 19521957.
27. Horlings HM, Lai C, Nuyten DS, Halfwerk H, Kristel P, van Beers E, Joosse SA, Klijn C, Nederlof PM, Reinders MJ, et al. Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Clin Cancer Res 2010, 16:651-663. 10.1158/1078-0432.CCR-09-0709, 20068109.